{"transactions":[{"id":1685487,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":95410,"kind":"person","name":"Freve Jonathan","position":1,"cik":"0001664466","reported_name":"Freve Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-01-05T16:00:07.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit represents the right to receive, at settlement, one share of common stock of Galecto, Inc.  One-third of the restricted stock units subject to the award will vest on January 3, 2025 and the remaining restricted stock units will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents the right to receive, at settlement, one share of common stock of Galecto, Inc.  One-third of the restricted stock units subject to the award will vest on January 3, 2025 and the remaining restricted stock units will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date."}],"balance_after":100000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-24-002430","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664466/000095017024002430/ownership.xml","form_type":"4"}},{"id":2062697,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":95410,"kind":"person","name":"Freve Jonathan","position":1,"cik":"0001664466","reported_name":"Freve Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-05T16:00:29.000Z","date":"2023-01-04","kind":"grant","acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vested and became exercisable on January 4, 2024 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":115000,"derivative":{"exercise_price":1.21,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001209191-23-001756","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664466/000120919123001756/doc4.xml","form_type":"4"}},{"id":2441570,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":95410,"kind":"person","name":"Freve Jonathan","position":1,"cik":"0001664466","reported_name":"Freve Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-06T17:00:13.000Z","date":"2022-01-04","kind":"grant","acquired":true,"shares":118750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vested and became exercisable on January 4, 2023 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":118750,"derivative":{"exercise_price":3.24,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":118750},"source":{"system":"sec-edgar","filing":"0001209191-22-002211","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664466/000120919122002211/doc4.xml","form_type":"4"}},{"id":2483777,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":95410,"kind":"person","name":"Freve Jonathan","position":1,"cik":"0001664466","reported_name":"Freve Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-06T08:00:08.000Z","date":"2021-12-03","kind":"purchase","acquired":true,"shares":4000,"price":2.49,"value":9960.0,"ownership":{"direct":true},"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001209191-21-068027","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664466/000120919121068027/doc4.xml","form_type":"4"}},{"id":2519622,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":95410,"kind":"person","name":"Freve Jonathan","position":1,"cik":"0001664466","reported_name":"Freve Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-09T08:00:10.000Z","date":"2021-11-08","kind":"purchase","acquired":true,"shares":3000,"price":3.4,"value":10200.0,"ownership":{"direct":true},"balance_after":8000,"source":{"system":"sec-edgar","filing":"0001209191-21-063523","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664466/000120919121063523/doc4.xml","form_type":"4"}},{"id":2596203,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":95410,"kind":"person","name":"Freve Jonathan","position":1,"cik":"0001664466","reported_name":"Freve Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-19T16:00:16.000Z","date":"2021-08-18","kind":"purchase","acquired":true,"shares":3000,"price":3.92,"value":11760.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-21-052512","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664466/000120919121052512/doc4.xml","form_type":"4"}},{"id":2657100,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":95410,"kind":"person","name":"Freve Jonathan","position":1,"cik":"0001664466","reported_name":"Freve Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-23T16:00:12.000Z","date":"2021-06-23","kind":"purchase","acquired":true,"shares":2000,"price":4.74,"value":9480.0,"ownership":{"direct":true},"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001209191-21-042719","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664466/000120919121042719/doc4.xml","form_type":"4"}},{"id":2913754,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":95410,"kind":"person","name":"Freve Jonathan","position":1,"cik":"0001664466","reported_name":"Freve Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-07T16:00:08.000Z","date":"2021-01-05","kind":"grant","acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vested and became exercisable on January 5, 2022 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":95000,"derivative":{"exercise_price":13,"expiration_date":"2031-01-05","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0001209191-21-002474","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664466/000120919121002474/doc4.xml","form_type":"4"}},{"id":3220546,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":95410,"kind":"person","name":"Freve Jonathan","position":1,"cik":"0001664466","reported_name":"Freve Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Treasurer"}}],"security":"Restricted Stock Units","published_at":"2020-03-09T16:10:11.000Z","date":"2020-03-05","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Spring Bank Pharmaceuticals, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units will vest in two installments. Fifty percent will vest on March 5, 2021 and the remaining fifty percent will vest on December 31, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units will vest in two installments. Fifty percent will vest on March 5, 2021 and the remaining fifty percent will vest on December 31, 2021."}],"balance_after":25000,"derivative":{"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-20-017230","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1664466/000120919120017230/doc4.xml","form_type":"4"}},{"id":3220545,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":95410,"kind":"person","name":"Freve Jonathan","position":1,"cik":"0001664466","reported_name":"Freve Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-09T16:10:11.000Z","date":"2020-03-05","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on March 5, 2020, with 25% of the shares subject to the option vesting on March 5, 2021 and the remaining 75% of the shares subject to the option vesting in 36 equal monthly installments thereafter."}],"balance_after":25000,"derivative":{"exercise_price":1.41,"expiration_date":"2030-03-04","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-20-017230","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664466/000120919120017230/doc4.xml","form_type":"4"}},{"id":3371324,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":95410,"kind":"person","name":"Freve Jonathan","position":1,"cik":"0001664466","reported_name":"Freve Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Treasurer"}}],"security":"Common Stock","published_at":"2019-11-14T16:08:01.000Z","date":"2019-11-14","kind":"purchase","acquired":true,"shares":5000,"price":3.04,"value":15200.0,"ownership":{"direct":true},"balance_after":17482,"source":{"system":"sec-edgar","filing":"0001209191-19-056558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664466/000120919119056558/doc4.xml","form_type":"4"}},{"id":3508869,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":95410,"kind":"person","name":"Freve Jonathan","position":1,"cik":"0001664466","reported_name":"Freve Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Treasurer"}}],"security":"Common Stock","published_at":"2019-05-29T10:16:41.000Z","date":"2019-05-29","kind":"purchase","acquired":true,"shares":5000,"price":5.4,"value":27000.0,"ownership":{"direct":true},"balance_after":12482,"source":{"system":"sec-edgar","filing":"0001209191-19-033132","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664466/000120919119033132/doc4.xml","form_type":"4"}},{"id":3686807,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":95410,"kind":"person","name":"Freve Jonathan","position":1,"cik":"0001664466","reported_name":"Freve Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-25T20:44:22.000Z","date":"2019-01-24","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 24, 2019, with 25% of the shares subject to the option vesting on January 24, 2020 and the remaining 75% of the shares subject to the option vesting in 36 equal monthly installments thereafter."}],"balance_after":50000,"derivative":{"exercise_price":10.35,"expiration_date":"2029-01-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-19-005451","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664466/000120919119005451/doc4.xml","form_type":"4"}},{"id":4097929,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":95410,"kind":"person","name":"Freve Jonathan","position":1,"cik":"0001664466","reported_name":"Freve Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-17T16:05:46.000Z","date":"2018-01-16","kind":"grant","acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 16, 2018, with 25% of the shares subject to the option vesting on January 16, 2019 and the remaining 75% of the shares subject to the option vesting in 36 equal monthly installments thereafter."}],"balance_after":27000,"derivative":{"exercise_price":12.1,"expiration_date":"2028-01-16","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001209191-18-003920","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664466/000120919118003920/doc4.xml","form_type":"4"}},{"id":4457253,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":95410,"kind":"person","name":"Freve Jonathan","position":1,"cik":"0001664466","reported_name":"Freve Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-10T16:24:19.000Z","date":"2017-02-09","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 9, 2017, with 25% of the shares subject to the option vesting on January 1, 2018 and the remaining 75% of the shares subject to the option vesting in 36 equal monthly installments thereafter."}],"balance_after":20000,"derivative":{"exercise_price":7.66,"expiration_date":"2027-02-09","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-17-009541","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664466/000120919117009541/doc4.xml","form_type":"4"}},{"id":4543186,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":95410,"kind":"person","name":"Freve Jonathan","position":1,"cik":"0001664466","reported_name":"Freve Jonathan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer & Secretary"}}],"security":"Warrant (right to buy)","published_at":"2016-11-23T16:02:57.000Z","date":"2016-11-23","kind":"grant","acquired":true,"shares":5482,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5482,"derivative":{"exercise_price":10.79,"exercise_date":"2017-05-24","expiration_date":"2021-11-23","underlying":"Common Stock","underlying_shares":5482},"source":{"system":"sec-edgar","filing":"0000899243-16-034299","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1664466/000089924316034299/doc4.xml","form_type":"4"}},{"id":4543185,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":95410,"kind":"person","name":"Freve Jonathan","position":1,"cik":"0001664466","reported_name":"Freve Jonathan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treasurer & Secretary"}}],"security":"Common Stock","published_at":"2016-11-23T16:02:57.000Z","date":"2016-11-23","kind":"grant","acquired":true,"shares":5482,"price":9.12,"value":49995.84,"ownership":{"direct":true},"balance_after":7482,"source":{"system":"sec-edgar","filing":"0000899243-16-034299","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664466/000089924316034299/doc4.xml","form_type":"4"}}]}